Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 16 de 16
Filtrar
1.
HIV Med ; 22(6): 502-511, 2021 07.
Artigo em Inglês | MEDLINE | ID: mdl-33728759

RESUMO

INTRODUCTION: Cognitive impairment has been reported in people living with HIV-1 (PLWH) with prior syphilis, while PLWH who present with incident syphilis have reduced blood CD4 T-lymphocyte and elevated HIV-1 RNA levels. However, the clinical, virological and neurocognitive effects of syphilis during acute HIV-1 (AHI) remain unknown. METHODS: Pre-antiretroviral therapy laboratory outcomes and neurocognitive performance in a four-test battery in the SEARCH10/RV254 AHI cohort were compared according to syphilis status, determined by serum Treponema pallidum haemagglutination (TPHA), Venereal Disease Research Laboratory (VDRL) and syphilis treatment history. Impaired cognitive performance was defined as having z-scores ≤ -1 in at least two tests or ≤ -2 in at least one test. RESULTS: Out of 595 AHI participants (97% male, median age of 26 years and estimated duration of HIV-1 infection of 19 days), 119 (20%) had history of syphilis (TPHA-positive), of whom 51 (9%) had untreated syphilis (TPHA-positive/VDRL-positive/without prior treatment). Compared with those without syphilis (TPHA-negative), individuals with untreated syphilis had higher CD8 T-lymphocyte levels but not higher plasma HIV-1 RNA or lower CD4 T-lymphocyte levels. Taking into account estimated duration of HIV-1 infection (P < 0.001), and later Fiebig stages (III-V) (P < 0.001), those with untreated syphilis had higher CD8 T-lymphocyte levels (P = 0.049). Individuals with any syphilis (TPHA-positive), but not untreated syphilis, had higher odds of impaired cognitive performance than those without (P = 0.002). CONCLUSIONS: During AHI, individuals with any history of syphilis (TPHA-positive) had poorer cognitive performance than those without syphilis. However, syphilis was not associated with worsened HIV disease measures as described in chronic infection.


Assuntos
Infecções por HIV , Soropositividade para HIV , Sífilis , Adulto , Feminino , Infecções por HIV/complicações , Testes de Hemaglutinação , Humanos , Laboratórios , Masculino , Sífilis/complicações , Sífilis/diagnóstico
2.
Artigo em Inglês | MEDLINE | ID: mdl-31258923

RESUMO

IMPORTANCE: Depression is a common co-morbidity for people living with HIV (PLWH) and is associated with elevated plasma HIV RNA levels. While depression correlates with deficits in antiretroviral (ARV) adherence, little data exist to inform the relationship between depression and HIV vial load more broadly. OBJECTIVE: To examine the relationship between depression and viral load in the African Cohort Study (AFRICOS) independently of ARV adherence. DESIGN: PLWH in Kenya, Uganda and Tanzania underwent screening for depression using the Center for Epidemiologic Studies Depression Scale (CESD) upon enrollment at AFRICOS HIV care sites. SETTING: AFRICOS is an ongoing prospective longitudinal cohort study enrolling HIV-infected adults at HIV care centers including sites in Kenya, Tanzania and Uganda. These sites are administered by President's Emergency Plan For AIDS Relief programs. PARTICIPANTS: HIV+ individuals were eligible if they were at least 18 years old, receiving HIV care at the enrolling clinic and consented to data and specimen collection. MAIN OUTCOME MEASURE: CESD. RESULTS: Among 2307 participants, 18-25% met the CESD threshold for depression. Depression was associated with decreased ARV adherence (OR 0.59, p =  0.01). Higher scores on three CESD items were significantly associated with 209-282% higher viral load, independently of ARV adherence among participants on ARVs ⩾6 months. CONCLUSIONS: PLWH had high prevalence of depression on the CESD. Diverse depression symptoms were independently associated with increases in viral load, underscoring the need for comprehensive treatment of depression.

3.
AJNR Am J Neuroradiol ; 39(12): 2211-2217, 2018 12.
Artigo em Inglês | MEDLINE | ID: mdl-30467218

RESUMO

BACKGROUND AND PURPOSE: The aging HIV-infected (HIV+) population has increased vascular comorbidities, including stroke, and increased cognitive deficits compared with the general population. Arterial spin-labeling is a technique to measure cerebral blood flow and is more sensitive than regional volume loss in assessing neurodegenerative diseases and cognitive aging. Previous studies have found global cerebral perfusion abnormalities in the HIV+ participants. In this study, we evaluated the specific regional pattern of CBF abnormalities in older HIV+ participants using quantitative whole-brain arterial spin-labeling. MATERIALS AND METHODS: CBF data from the UCSF HIV Over 60 Cohort and the Alzheimer Disease Neuroimaging Initiative were retrospectively evaluated to identify 19 HIV+ older adults, all with plasma viral suppression (including 5 with HIV-associated neurocognitive disorder); 13 healthy, age-matched controls; and 19 participants with early mild cognitive impairment. CBF values were averaged by ROI and compared among the 3 groups using generalized linear models. RESULTS: When we accounted for age, education, sex, and vascular risk factors, the HIV+ participants demonstrated alterations in regional cerebral perfusion, including hypoperfusion of bilateral temporal, parietal, and occipital brain regions compared with both clinically healthy participants and those with mild cognitive impairment. Arterial spin-labeling showed reasonable test characteristics in distinguishing those with HIV-associated neurocognitive disorder from healthy controls and participants with mild cognitive impairment. CONCLUSIONS: This study found specific CBF patterns associated with HIV status despite viral suppression-data that should animate further investigations into the pathobiologic basis of vascular and cognitive abnormalities in HIV-associated neurocognitive disorders.


Assuntos
Complexo AIDS Demência/diagnóstico por imagem , Complexo AIDS Demência/fisiopatologia , Circulação Cerebrovascular/fisiologia , Neuroimagem/métodos , Idoso , Encéfalo/irrigação sanguínea , Encéfalo/diagnóstico por imagem , Feminino , Humanos , Imageamento por Ressonância Magnética/métodos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Marcadores de Spin
4.
J Neurovirol ; 18(1): 69-73, 2012 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-22207583

RESUMO

HIV-associated neurocognitive disorders (HAND) persist despite plasma HIV RNA suppression with antiretrovirals (ARV). Sequestered reservoirs in the central nervous system and circulating monocytes are theorized to contribute to persistent brain injury. We previously demonstrated that elevated intracellular HIV DNA from circulating cells was associated with HAND in ARV-treated and ARV-naive subjects. We now report that failure to suppress intra-monocyte HIV DNA 3.5 years after initiating ARV is linked to persistent HAND and subjects with dementia are least likely to suppress intra-monocyte HIV DNA at 3.5 years. These findings suggest that antiviral strategies may need to target intra-monocyte HIV DNA.


Assuntos
Complexo AIDS Demência/fisiopatologia , Fármacos Anti-HIV/uso terapêutico , Encéfalo/fisiopatologia , Citosol/virologia , DNA Viral/biossíntese , Monócitos/virologia , Complexo AIDS Demência/tratamento farmacológico , Complexo AIDS Demência/virologia , Fármacos Anti-HIV/administração & dosagem , Encéfalo/virologia , Citosol/efeitos dos fármacos , Quimioterapia Combinada , Humanos , Estudos Longitudinais , Monócitos/efeitos dos fármacos , Testes Neuropsicológicos , Falha de Tratamento
5.
Neurology ; 72(11): 992-8, 2009 Mar 17.
Artigo em Inglês | MEDLINE | ID: mdl-19289739

RESUMO

OBJECTIVES: The extent to which highly active antiretroviral therapy (HAART) era cognitive disorders are due to active processes, incomplete clearance of reservoirs, or comorbidities is controversial. This study aimed to determine if immunologic and virologic factors influence cognition after first-time HAART in Thai individuals with HIV-associated dementia (HAD) and Thai individuals without HAD (non-HAD). METHODS: Variables were captured longitudinally to determine factors predictive of degree of cognitive recovery after first-time HAART. Neuropsychological data were compared to those of 230 HIV-negative Thai controls. RESULTS: HIV RNA and CD4 lymphocyte counts were not predictive of HAD cross-sectionally or degree of cognitive improvement longitudinally. In contrast, baseline and longitudinal HIV DNA isolated from monocytes correlated to cognitive performance irrespective of plasma HIV RNA and CD4 lymphocyte counts pre-HAART (p < 0.001) and at 48 weeks post HAART (p < 0.001). Levels exceeding 3.5 log(10) copies HIV DNA/10(6) monocyte at baseline distinguished all HAD and non-HAD cases (p < 0.001). At 48 weeks, monocyte HIV DNA was below the level of detection of our assay (10 copies/10(6) cells) in 15/15 non-HAD compared to only 4/12 HAD cases, despite undetectable plasma HIV RNA in 26/27 cases. Baseline monocyte HIV DNA predicted 48-week cognitive performance on a composite score, independently of concurrent monocyte HIV DNA and CD4 count (p < 0.001). CONCLUSIONS: Monocyte HIV DNA level correlates to cognitive performance before highly active antiretroviral therapy (HAART) and 48 weeks after HAART in this cohort and baseline monocyte HIV DNA may predict 48-week cognitive performance. These findings raise the possibility that short-term incomplete cognitive recovery with HAART may represent an active process related to this peripheral reservoir.


Assuntos
Complexo AIDS Demência/sangue , Complexo AIDS Demência/psicologia , Terapia Antirretroviral de Alta Atividade , Cognição , DNA Viral/sangue , HIV/genética , Adulto , Separação Celular , Estudos de Coortes , Estudos Transversais , Feminino , Humanos , Receptores de Lipopolissacarídeos/sangue , Estudos Longitudinais , Masculino , Monócitos/metabolismo , Testes Neuropsicológicos , Estudos Prospectivos , Tailândia
6.
HIV Med ; 10(2): 103-10, 2009 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-19200173

RESUMO

OBJECTIVES: Antiretroviral toxic neuropathy (ATN) is associated with dideoxynucleoside reverse transcriptase inhibitor use in patients infected with HIV, possibly as a result of mitochondrial toxicity. Acetyl-l-carnitine (ALC) has been linked to symptomatic improvement in ATN. We present an open-label single-arm pilot study to evaluate changes in intra-epidermal nerve fibre (IENF) density and mitochondrial DNA (mtDNA) copies/cell among subjects treated with 3000 mg ALC daily. METHODS: Punch skin biopsies were examined at baseline and after 24 weeks of therapy. Participants reported neuropathic symptoms using the Gracely Pain Intensity Score. Neurological examinations were completed. RESULTS: Twenty-one subjects completed the study. ALC was generally well tolerated. The IENF density did not change in cases completing 24 weeks of ALC therapy, with median (90% confidence interval) IENF changes of -1.70 (-3.50, infinity) (P=0.98) and 2.15 (-0.10, infinity) (P=0.11) for the distal leg and proximal thigh, respectively. Fat mtDNA copies/cell did not change with therapy. Improvements in neuropathic pain (P<0.01), paresthesias (P=0.01), and symptoms of numbness (P<0.01) were noted. Similarly, improvement was noted on the Gracely Pain Intensity Score. CONCLUSIONS: ALC therapy coincided with improvements in subjective measures of pain in this open-label single-arm study. However, changes were not observed in objective measures of IENF density or mtDNA levels, providing little objective support for use of ALC in this setting.


Assuntos
Infecções Oportunistas Relacionadas com a AIDS/tratamento farmacológico , Acetilcarnitina/efeitos adversos , HIV-1 , Doenças do Sistema Nervoso Periférico/tratamento farmacológico , Inibidores da Transcriptase Reversa/efeitos adversos , Infecções Oportunistas Relacionadas com a AIDS/induzido quimicamente , Infecções Oportunistas Relacionadas com a AIDS/patologia , Intervalos de Confiança , DNA Mitocondrial/efeitos dos fármacos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Fibras Nervosas/efeitos dos fármacos , Fibras Nervosas/patologia , Medição da Dor , Doenças do Sistema Nervoso Periférico/induzido quimicamente , Doenças do Sistema Nervoso Periférico/patologia , Projetos Piloto
7.
Neurology ; 69(18): 1789-99, 2007 Oct 30.
Artigo em Inglês | MEDLINE | ID: mdl-17914061

RESUMO

In 1991, the AIDS Task Force of the American Academy of Neurology published nomenclature and research case definitions to guide the diagnosis of neurologic manifestations of HIV-1 infection. Now, 16 years later, the National Institute of Mental Health and the National Institute of Neurological Diseases and Stroke have charged a working group to critically review the adequacy and utility of these definitional criteria and to identify aspects that require updating. This report represents a majority view, and unanimity was not reached on all points. It reviews our collective experience with HIV-associated neurocognitive disorders (HAND), particularly since the advent of highly active antiretroviral treatment, and their definitional criteria; discusses the impact of comorbidities; and suggests inclusion of the term asymptomatic neurocognitive impairment to categorize individuals with subclinical impairment. An algorithm is proposed to assist in standardized diagnostic classification of HAND.


Assuntos
Complexo AIDS Demência/diagnóstico , Complexo AIDS Demência/fisiopatologia , Pesquisa , Complexo AIDS Demência/patologia , Complexo AIDS Demência/terapia , Academias e Institutos , Algoritmos , Terapia Antirretroviral de Alta Atividade , Transtornos Cognitivos/classificação , Transtornos Cognitivos/diagnóstico , Transtornos Cognitivos/etiologia , Transtornos Cognitivos/virologia , Progressão da Doença , HIV-1 , Humanos , Testes Neuropsicológicos
8.
Neurology ; 69(13): 1314-21, 2007 Sep 25.
Artigo em Inglês | MEDLINE | ID: mdl-17652642

RESUMO

BACKGROUND: Cognitive impairment continues to be a significant neurologic complication of HIV infection and has been associated with oxidative stress-induced neuronal injury. Selegiline is an MAO-B inhibitor with antioxidant and neurotrophic properties. This rationale has led to the design and implementation of this Selegiline Transdermal System (STS) study with the primary aims of assessing safety and tolerability of STS as well as improvement in cognitive performance. METHODS: HIV-1 infected individuals with impaired cognitive functioning were enrolled in this placebo-controlled, three-arm study of STS across 17 sites. Cognitive impairment was determined using a standard battery of neuropsychological tests. Subjects were randomized to receive STS 3 mg/24 hours, STS 6 mg/24 hours, or matching placebo patches daily. The primary efficacy endpoint was defined as the change in neuropsychological composite Z-score (NPZ-6) from baseline to week 24. Measures of safety included frequencies of adverse experiences and abnormal results on laboratory tests. RESULTS: A total of 128 subjects (88% men, 51% white) were enrolled, median age 45 years. Most subjects (62%) had mild to moderate AIDS dementia complex. The 24-week NPZ-6 median (interquartile range) changes were 0.22 (-0.28, 0.55) for the selegiline 3 mg/24 hours arm, 0.21 (-0.18, 0.62) for the selegiline 6 mg/24 hours arm, and 0.28 (-0.16, 0.64) for the placebo arm (a positive score indicates improvement from baseline) (p = 0.914). Severe laboratory abnormalities were few and occurred in similar proportion among the three treatment arms. CONCLUSION: Selegiline was safe and well tolerated by HIV-infected individuals with cognitive impairment and mild to moderate immune suppression; however, no cognitive or functional improvement was observed in this phase II study.


Assuntos
Complexo AIDS Demência/tratamento farmacológico , Antioxidantes/administração & dosagem , Citoproteção/efeitos dos fármacos , Fármacos Neuroprotetores/administração & dosagem , Selegilina/administração & dosagem , Complexo AIDS Demência/diagnóstico , Complexo AIDS Demência/psicologia , Adulto , Idoso , Encéfalo/efeitos dos fármacos , Encéfalo/fisiopatologia , Encéfalo/virologia , Citoproteção/fisiologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Degeneração Neural/tratamento farmacológico , Degeneração Neural/prevenção & controle , Degeneração Neural/virologia , Fármacos Neuroprotetores/efeitos adversos , Testes Neuropsicológicos , Placebos , Selegilina/efeitos adversos , Falha de Tratamento
9.
Neurology ; 68(24): 2113-9, 2007 Jun 12.
Artigo em Inglês | MEDLINE | ID: mdl-17562831

RESUMO

OBJECTIVE: To demonstrate the relationship between epidermal nerve fiber density (ENFD) in the leg and the phenotype of HIV-associated distal sensory polyneuropathy (HIV-DSP) in a multicenter prospective study (ACTG A5117). METHODS: A total of 101 HIV-infected adults, with CD4 cell count <300 cells/mm(3) and who had received antiretroviral therapy (ART) for at least 15 consecutive weeks, underwent standardized clinical and electrophysiologic assessment. All 101 subjects were biopsied at the distal leg (DL) and 99 at the proximal thigh (PT) at baseline. ENFD was assessed by skin biopsy using PGP9.5 immunostaining. Associations of ENFD with demographics, ART treatment, Total Neuropathy Score (TNS), sural sensory nerve action potential (SNAP) amplitude and conduction velocity, quantitative sensory testing (QST) measures, and neuropathic pain were explored. RESULTS: ENFD at the DL site correlated with neuropathy severity as gauged by TNS (p < 0.01), the level of neuropathic pain quantified by the Gracely Pain Scale (GPS) (p = 0.01) and Visual Analogue Scale (VAS) (p = 0.01), sural SNAP amplitude (p < 0.01), and toe cooling (p < 0.01) and vibration (p = 0.02) detection thresholds. ENFD did not correlate with neurotoxic ART exposure, CD4 cell count, or plasma HIV-1 viral load. CONCLUSIONS: In subjects with advanced HIV-1 infection, epidermal nerve fiber density (ENFD) assessment correlates with the clinical and electrophysiologic severity of distal sensory polyneuropathy (DSP). ENFD did not correlate with previously established risk factors for HIV-DSP, including CD4 cell count, plasma HIV-1 viral load, and neurotoxic antiretroviral therapy exposure.


Assuntos
Infecções por HIV/complicações , Fibras Nervosas/patologia , Nervos Periféricos/patologia , Doenças do Sistema Nervoso Periférico/patologia , Células Receptoras Sensoriais/patologia , Potenciais de Ação/fisiologia , Adulto , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Fibras Nervosas/virologia , Condução Nervosa/fisiologia , Neuralgia/patologia , Neuralgia/fisiopatologia , Neuralgia/virologia , Medição da Dor , Nervos Periféricos/fisiopatologia , Nervos Periféricos/virologia , Doenças do Sistema Nervoso Periférico/fisiopatologia , Doenças do Sistema Nervoso Periférico/virologia , Fenótipo , Estudos Prospectivos , Células Receptoras Sensoriais/fisiopatologia , Células Receptoras Sensoriais/virologia , Pele/inervação , Pele/patologia , Pele/fisiopatologia , Nervo Sural/patologia , Nervo Sural/fisiopatologia , Nervo Sural/virologia
10.
Neurology ; 68(7): 525-7, 2007 Feb 13.
Artigo em Inglês | MEDLINE | ID: mdl-17296919

RESUMO

HIV-associated dementia (HAD) is not firmly established in patients with circulating recombinant form (CRF) 01_AE HIV-1. In this study, we compared neuropsychological performance among 15 Thai individuals with HAD, 15 Thai individuals without HAD, and 30 HIV-negative control subjects. HIV-1 participants were highly active anti-retroviral therapy naive and matched by age, education, and CD4 count. Neuropsychological testing abnormalities were identified in most cognitive domains among HAD vs HIV-negative participants, confirming the presence of HAD in CRF01_AE.


Assuntos
Complexo AIDS Demência/virologia , HIV-1/classificação , HIV-1/genética , Transtornos Mentais/virologia , Doenças do Sistema Nervoso/virologia , Recombinação Genética , Complexo AIDS Demência/sangue , Complexo AIDS Demência/psicologia , Adulto , Cognição , Estudos de Coortes , Feminino , Humanos , Masculino , Testes Neuropsicológicos , Índice de Gravidade de Doença
11.
Cell Mol Biol (Noisy-le-grand) ; 51 Suppl: OL745-54, 2005 Sep 02.
Artigo em Inglês | MEDLINE | ID: mdl-16171574

RESUMO

Monocytes and macrophages serve as HIV-1 reservoirs and may indirectly lead to HIV-1-associated dementia via neurotoxic cytokine/chemokine production. It remains unknown if peripheral monocytes and macrophages are responsible for the presence of circulating and cerebral spinal fluid cytokine/chemokine. The purpose of this evaluation was to determine the relationship between inflammatory and chemoattractant cytokine/chemokine in the periphery and the CNS among individuals with HIV-1-associated dementia and normal cognition. To accomplish this, we utilized specimens from the Hawaii Aging with HIV Cohort to assay plasma, cerebral spinal fluid, and cultured peripheral monocyte and macrophage supernatant cytokine/chemokines from individuals with HIV-1-associated dementia and normal cognition by ELISA, relative real-time PCR, and protein macroarrays. To further characterize the activated cells that may be responsible for HIV-1-associated dementia, inverse-PCR was used to identify sites of viral integration. Different mediators of inflammation, and chemoattraction from monocyte and macrophage supernatants, plasma, and cerebral spinal fluid were identified in HIV-1-associated dementia versus normal cognition. The data suggest unique pathways leading to cytokine/chemokine release in the periphery versus the brain region. This may have implications in delineating a cause and effect in HIV-1-associated dementia pathogenesis.


Assuntos
Complexo AIDS Demência/sangue , Complexo AIDS Demência/líquido cefalorraquidiano , Quimiocinas/sangue , Quimiocinas/líquido cefalorraquidiano , Complexo AIDS Demência/imunologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Estudos de Casos e Controles , Ensaio de Imunoadsorção Enzimática , Feminino , Humanos , Receptores de Lipopolissacarídeos , Macrófagos/metabolismo , Masculino , Pessoa de Meia-Idade , Modelos Biológicos , Valor Preditivo dos Testes , Análise Serial de Proteínas , Receptores de IgG , Frações Subcelulares
12.
J Neuroimmunol ; 157(1-2): 197-202, 2004 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-15579298

RESUMO

There are discrepant findings regarding the risk of HIV-associated dementia (HAD) relating to apolipoprotein E4, suggesting other factors may modulate risk. Furthermore, evidence suggests a changing phenotype of HAD in the era of highly active antiretroviral therapy (HAART), prompting a need to determine if new disease markers have emerged. In this analysis, APOE genotype was determined for 182 participants enrolled in the Hawaii Aging with HIV Cohort. After controlling for age and diabetes status, an independent risk of HAD relating to E4 was seen in older participants [OR=2.898 (1.031-8.244)] but not in younger participants [OR=0.373 (0.054-1.581)]. Several proposed mechanisms may underlie this association. Consideration of non-traditional risk factors for HAD in older HIV patients may yield new markers of disease in the era of HAART.


Assuntos
Complexo AIDS Demência/metabolismo , Envelhecimento/fisiologia , Apolipoproteínas E/metabolismo , Infecções por HIV/metabolismo , Risco , Complexo AIDS Demência/epidemiologia , Complexo AIDS Demência/genética , Complexo AIDS Demência/terapia , Adulto , Terapia Antirretroviral de Alta Atividade/métodos , Apolipoproteína E4 , Apolipoproteínas E/genética , Estudos de Coortes , Feminino , Infecções por HIV/epidemiologia , Infecções por HIV/genética , Havaí/epidemiologia , Humanos , Masculino , Pessoa de Meia-Idade , Fenótipo
13.
Neurology ; 63(5): 822-7, 2004 Sep 14.
Artigo em Inglês | MEDLINE | ID: mdl-15365130

RESUMO

BACKGROUND: Antiretroviral therapy has improved survival for HIV-1-infected individuals. The neuroepidemiologic implications of HIV-1 in an aging population are not well known, particularly the prevalence of HIV-associated dementia (HAD). METHODS: The authors report a baseline cross-sectional analysis of 202 HIV-1-seropositive individuals enrolled into one of two groups of the Hawaii Aging with HIV Cohort: older (50 or more years old, n = 106) and younger (20 to 39 years old, n = 96). Neuropsychological, neurologic, medical, and laboratory data were obtained at enrollment. Participant cognitive status was classified (research case definitions) using American Academy of Neurology (1991) criteria in a consensus conference of physicians and neuropsychologists. RESULTS: HAD was more frequent in older (25.2%) compared to younger (13.7%) individuals (p = 0.041) corresponding to an OR of 2.13 (95% CI: 1.02 to 4.44) for the older compared to the younger group. After adjusting for education, race, substance dependence, antiretroviral medication status, viral load, CD4 lymphocyte count, and Beck Depression Inventory score, the odds of having HAD among individuals in the older group was 3.26 (1.32 to 8.07) times that of the younger group. CONCLUSIONS: Older age is associated with increased HAD in this HIV-1 cohort. Underlying mechanisms are unclear but do not appear related to duration of HIV-1 infection.


Assuntos
Complexo AIDS Demência/epidemiologia , Envelhecimento/psicologia , Infecções por HIV/psicologia , HIV-1 , Adulto , Idoso , Fármacos Anti-HIV/uso terapêutico , Contagem de Linfócito CD4 , Transtornos Cognitivos/epidemiologia , Estudos de Coortes , Estudos Transversais , Depressão/epidemiologia , Feminino , Infecções por HIV/tratamento farmacológico , Havaí/epidemiologia , Humanos , Masculino , Pessoa de Meia-Idade , Testes Neuropsicológicos , Fatores de Risco , Carga Viral
14.
Neurology ; 62(8): 1378-83, 2004 Apr 27.
Artigo em Inglês | MEDLINE | ID: mdl-15111677

RESUMO

OBJECTIVE: To determine if aging changes the frequency, severity, or manifestations of symptomatic distal sensory polyneuropathy (SxDSPN) in patients with HIV-1. METHODS: Prospective observations of 70 older (age < or = 50) and 56 younger (age 20 to 40) patients with HIV, and a control group of 48 older non-HIV patients, were conducted utilizing neurologic examination, neuropsychological testing, lumbar puncture, laboratory, and medical history. RESULTS: The frequency of SxDSPN among older HIV patients was 50.4%, compared to 19.6% among younger HIV patients (p < 0.001). SxDSPN among control patients occurred in 4.2%, similar to the general population. Older compared to younger HIV patients demonstrated more severe symptoms (p = 0.02) and greater deficits for vibration (p < 0.01). Increasing numbers of neuropathic comorbidities among older compared to younger HIV patients were associated with increasing severity of deficits to pinprick (p = 0.003). Dementia and SxDSPN coexisted in 36% of the older HIV patients and in none of the younger HIV patients (p = 0.021). Older HIV patients with nadir CD4 < or =200 cells/mL were 4.23 times as likely to have SxDSPN than older patients with nadir CD4 >200 cells/mL (p = 0.007). Vibratory deficits excessive to pinprick deficits predicted SxDSPN among older (OR 2.83) but not younger seropositive patients (p = 0.036). CONCLUSIONS: Age > or = 50 increases the frequency of SxDSPN, and is associated with both vibratory loss as the predominant sensory deficit and increased severity of pinprick loss among symptomatic patients with neuropathic comorbidities. SxDSPN is associated with both dementia and low nadir CD4 in HIV-positive patients aged 50 and greater.


Assuntos
Complexo AIDS Demência/epidemiologia , Infecções por HIV/epidemiologia , Soropositividade para HIV/epidemiologia , HIV-1 , Polineuropatias/epidemiologia , Complexo AIDS Demência/imunologia , Complexo AIDS Demência/virologia , Adulto , Distribuição por Idade , Fatores Etários , Idoso , Envelhecimento/imunologia , Contagem de Linfócito CD4 , Estudos de Coortes , Comorbidade , Estudos Transversais , Infecções por HIV/imunologia , Infecções por HIV/virologia , Soropositividade para HIV/imunologia , Soropositividade para HIV/virologia , Havaí/epidemiologia , Humanos , Estudos Longitudinais , Pessoa de Meia-Idade , Polineuropatias/imunologia , Polineuropatias/virologia , Prevalência , Estudos Prospectivos , Índice de Gravidade de Doença
15.
Arch Intern Med ; 160(19): 2964-8, 2000 Oct 23.
Artigo em Inglês | MEDLINE | ID: mdl-11041904

RESUMO

BACKGROUND: Recognition and medical record documentation of dementia in the primary care setting are thought to be poor. To our knowledge, previous studies have not examined these issues in private practice office settings within the United States. OBJECTIVE: To determine the rate of unrecognized and undocumented dementia in a primary care internal medicine private practice. METHODS: This was a cross-sectional study of 297 ambulatory persons aged 65 years and older attending an internal medicine private group practice within an Asian American community of Honolulu, Hawaii. Of the subjects, 95% had been with their current primary care physician for at least 1 year. Each subject's primary care physician noted the presence or absence of dementia by questionnaire at the time of an office visit. An investigating physician (V.G.V.) subsequently assessed cognitive function using the Cognitive Abilities Screening Instrument, and confirmed the presence of dementia and its severity, if present, using Benson and Cummings' criteria and the Clinical Dementia Rating Scale, respectively. A trained research assistant completed telephone interviews to proxy informants for collateral information concerning cognition, behavior, and occupational or social function. Subjects' outpatient medical records were reviewed for documentation of problems with cognition. RESULTS: Twenty-six cases of dementia were identified. Of these 26, 17 (65%) (95% confidence interval, 44.3-82.8) were not documented in outpatient medical records; of 18 patients, 12 (67%) (95% confidence interval, 40.9-86.7) were not thought to have dementia by their physicians at the time of the office visit. Recognition and documentation rates increased with advancing stage of disease. CONCLUSION: Dementia is often unrecognized and undocumented in private practice settings. Arch Intern Med. 2000;160:2964-2968


Assuntos
Demência/diagnóstico , Avaliação Geriátrica , Atenção Primária à Saúde , Idoso , Transtornos Cognitivos/diagnóstico , Estudos Transversais , Feminino , Havaí , Humanos , Modelos Logísticos , Masculino , Testes Psicológicos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA